Zevra Therapeutics Inc Ordinary Shares ZVRA 深 沪
等待开盘 10-25 09:30:00 美东时间
10.61
-0.070
-0.66%
华盛通- 最 高10.91
- 今 开10.79
- 成交量 70.69万股
- 最 低 10.56
- 昨 收 10.68
- 总市值 5.80亿
- 52周最高 13.16
- 市盈率 静 --
- 换手率 1.29%
- 52周最低 6.19
- 委 比 42.07%
- 总股本 5467.96万
- 历史最高 418.40
- 量 比 0.70
- 振 幅 3.28%
- 历史最低 0.206
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics granted 38,000 stock options to two new employees under its 2023 Inducement Award Plan. The options vest over four years, with 25% vesting on the first anniversary and the remainder in three equal annual installments. The grants were approved by the Compensation Committee and align with Nasdaq Rule 5635(c)(4). Zevra focuses on developing therapies for rare diseases. For more information, visit www.zevra.com.
10-06 21:51
Zevra Therapeutics rises amid takeover speculation
Zevra Therapeutics gained 7.5% amid some takeover speculation. Collegium Pharmaceuticals (COLL) was looking at purchasing Zevra Therapeutics, though it couldn't get the financing for a potential deal,...
09-25 22:37
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.
09-25 18:11
Alvin Shih Adds To Zevra Therapeutics Holding
Investors who take an interest in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) should...
09-19 02:41
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)
Zevra Therapeutics will present clinical data on MIPLYFFA and OLPRUVA at upcoming meetings. MIPLYFFA, the only therapy shown to halt Niemann-Pick disease type C progression, has treated over 270 patients. OLPRUVA offers a novel formulation for urea cycle disorders. Presentations will review long-term evidence for disease modification, pediatric sub-study results, and safety/efficacy findings. MIPLYFFA increases TFEB/TFE3 activation, reducing lyso...
09-18 11:30
Zevra Therapeutics Presents Several Posters Highlighting New Data On MIPLYFFA For Treatment Of Niemann-Pick Disease Type C At ICIEM
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progressionNomination for Best Poster Award received for poster
09-04 19:33
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Zevra Therapeutics To Present Four Posters On MIPLYFFA At ICIEM 2025
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA® (MY-PLY-FAH)
08-28 19:32
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
Zevra Therapeutics will present four posters on MIPLYFFA (arimoclomol), its approved therapy for Niemann-Pick disease type C (NPC), at the International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. The posters highlight MIPLYFFA's mechanism of action, safety, efficacy, and real-world outcomes, including a pediatric substudy and a prespecified efficacy analysis. One poster received a Best Poster award for its focus on MIPLYFFA'...
08-28 11:30
Zevra Therapeutics to Participate at Upcoming Investor Conferences in September
Zevra Therapeutics announced that its leadership team will attend two healthcare conferences in September: the Cantor Global Healthcare Conference on Sept. 3 and the H.C. Wainwright Annual Global Investment Conference on Sept. 8. They will also hold one-on-one meetings with attendees. The company specializes in developing therapies for rare diseases and aims to address unmet medical needs. (168 characters)
08-26 11:30
